Summit Therapeutics (SMMT) Tops Q1 EPS by 2c

Summit Therapeutics (NASDAQ: SMMT) reported Q1 EPS of (GBP0.07), GBP0.02 better than the analyst estimate of (GBP0.09).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Summit Therapeutics plc (SMMT) PT Raised to $9.80 at Bernstein SocGen Group
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• UBS Reiterates Neutral Rating on Brenntag AG (BNR:GR) (BNTGY)